CASI Pharmaceuticals Inc (CASI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has a cash flow conversion efficiency ratio of -0.014x as of March 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-843.00K) by net assets ($62.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CASI stock market capitalisation for the company's overall valuation and market capitalisation.
CASI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CASI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore CASI Pharmaceuticals Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Invibes Advertising NV
PA:ALINV
|
-0.215x |
|
Opawica Explorations Inc
V:OPW
|
-0.022x |
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
-0.171x |
|
Century Global Commodities Corp
TO:CNT
|
-0.047x |
|
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
|
-0.054x |
|
Noram Lithium Corp
V:NRM
|
-0.023x |
|
Horus AG
STU:HRU
|
N/A |
|
Alliance Pharma plc
LSE:APH
|
0.099x |
Annual Cash Flow Conversion Efficiency for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of CASI Pharmaceuticals Inc from 1994 to 2024. View CASI Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.85 Million | $-29.22 Million | -15.788x | -1810.76% |
| 2023-12-31 | $24.16 Million | $-19.97 Million | -0.826x | -162.26% |
| 2022-12-31 | $66.93 Million | $-21.09 Million | -0.315x | -26.72% |
| 2021-12-31 | $107.96 Million | $-26.84 Million | -0.249x | +0.52% |
| 2020-12-31 | $103.57 Million | $-25.89 Million | -0.250x | -0.72% |
| 2019-12-31 | $93.67 Million | $-23.24 Million | -0.248x | +4.97% |
| 2018-12-31 | $109.46 Million | $-28.58 Million | -0.261x | -57.19% |
| 2017-12-31 | $38.54 Million | $-6.40 Million | -0.166x | +42.68% |
| 2016-12-31 | $20.78 Million | $-6.02 Million | -0.290x | -132.00% |
| 2015-12-31 | $-6.09 Million | $-5.51 Million | 0.906x | -90.43% |
| 2014-12-31 | $-422.21K | $-4.00 Million | 9.463x | +4416.67% |
| 2013-12-31 | $14.94 Million | $-3.28 Million | -0.219x | +18.39% |
| 2012-12-31 | $8.24 Million | $-2.21 Million | -0.269x | +84.08% |
| 2011-12-31 | $2.53 Million | $-4.27 Million | -1.687x | -81.46% |
| 2010-12-31 | $5.33 Million | $-4.96 Million | -0.930x | -117.54% |
| 2009-12-31 | $-1.93 Million | $-10.21 Million | 5.303x | +251.61% |
| 2008-12-31 | $5.92 Million | $-20.71 Million | -3.498x | -299.91% |
| 2007-12-31 | $26.90 Million | $-23.52 Million | -0.875x | -97.78% |
| 2006-12-31 | $46.98 Million | $-20.77 Million | -0.442x | +10.49% |
| 2005-12-31 | $29.39 Million | $-14.52 Million | -0.494x | -7.57% |
| 2004-12-31 | $35.72 Million | $-16.41 Million | -0.459x | +33.95% |
| 2003-12-31 | $34.88 Million | $-24.25 Million | -0.695x | +83.95% |
| 2002-12-31 | $10.51 Million | $-45.53 Million | -4.332x | -90.19% |
| 2001-12-31 | $23.21 Million | $-52.87 Million | -2.278x | +1.89% |
| 2000-12-31 | $19.06 Million | $-44.25 Million | -2.322x | -42.68% |
| 1999-12-31 | $22.00 Million | $-35.80 Million | -1.627x | -332.20% |
| 1998-12-31 | $33.20 Million | $-12.50 Million | -0.377x | -140.17% |
| 1997-12-31 | $42.10 Million | $-6.60 Million | -0.157x | -239.90% |
| 1996-12-31 | $47.70 Million | $-2.20 Million | -0.046x | +96.26% |
| 1995-12-31 | $3.60 Million | $-4.44 Million | -1.233x | +94.33% |
| 1994-12-31 | $200.00K | $-4.35 Million | -21.750x | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more